TP53 and prostate carcinoma: Because we are not aware of previous studies taking a similar approach for prostate cancer, we extensively compared our gene-level sCNA estimates to panel-based sequencing and Oncoscan data for a subset of BL patients, as well as to genetically validated and previously published PTEN and p53 IHC assays in the entire cohort (25, 29).